At the time of writing, UroGen Pharma Ltd [URGN] stock is trading at $16.93, down -2.08%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The URGN shares have gain 3.11% over the last week, with a monthly amount drifted -6.46%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on August 19, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $36. Previously, H.C. Wainwright upgraded its rating to Buy on June 16, 2025, and kept the price target unchanged to $50. On May 22, 2025, downgrade downgraded it’s rating to Neutral. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $23 on April 16, 2025. Guggenheim started tracking with a Buy rating for this stock on August 22, 2024, and assigned it a price target of $40. In a note dated February 08, 2023, Jefferies downgraded a Hold rating on this stock and revised its target price from $35 to $10.
For the past year, the stock price of UroGen Pharma Ltd fluctuated between $3.42 and $21.71. Currently, Wall Street analysts expect the stock to reach $23.5 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $16.93 at the most recent close of the market. An investor can expect a potential return of 38.81% based on the average URGN price forecast.
Analyzing the URGN fundamentals
According to UroGen Pharma Ltd [NASDAQ:URGN], the company’s sales were 94.24M for trailing twelve months, which represents an 10.83% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.31%, Pretax Profit Margin comes in at -1.6%, and Net Profit Margin reading is -1.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.74, Equity is 5.03 and Total Capital is -0.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.68 points at the first support level, and at 16.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.41, and for the 2nd resistance point, it is at 17.89.
Ratios To Look Out For
It is important to note that UroGen Pharma Ltd [NASDAQ:URGN] has a current ratio of 4.14. As well, the Quick Ratio is 3.99, while the Cash Ratio is 1.95. Considering the valuation of this stock, the price to sales ratio is 8.31.
Transactions by insiders
Recent insider trading involved Degnan Chris, Chief Financial Officer, that happened on Oct 08 ’25 when 2203.0 shares were sold. Chief Medical Officer, Schoenberg Mark completed a deal on Sep 08 ’25 to sell 871.0 shares. Meanwhile, General Counsel Smith Jason Drew sold 1520.0 shares on Sep 08 ’25.
